Mainz Biomed N.V (MYNZ) said Tuesday it has partnered with Thermo Fisher Scientific (TMO) to develop a colorectal cancer screening test.
Financial details of the partnership were not disclosed.
Mainz said the partnership will combine its experience in mRNA-based colorectal cancer detection with Thermo Fisher's technology resources to develop a non-invasive test for detecting early-stage colorectal cancer and precancerous growths.
Shares of Mainz Biomed rose nearly 7% in recent Tuesday trading, while Thermo Fisher's rose 0.3%.
Price: 0.23, Change: +0.01, Percent Change: +6.51
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。